CoChat

A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis

Open access
Rinella, Mary E., Lieu, Hsiao D., Kowdley, Kris V., Goodman, Zachary D., Alkhouri, Naim, Lawitz, Eric, Ratziu, Vlad, Abdelmalek, Manal F., Wong, Vincent Wai-Sun, Younes, Ziad H., Sheikh, Aasim M., Brannan, Donald, Freilich, Bradley, Membreno, Fernando, Sinclair, Marie, Melchor-Khan, Liza, Sanyal, Arun J., Ling, Lei, Harrison, Stephen A. · 2024 · Hepatology
Cited by 94

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background and Aims: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with noncirrhotic NASH; however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonstrate benefit in the compensated NASH population. Approach and Results: In this multicenter, double-blind, placebo-controlled, phase 2b trial, 160 patients with compensated NASH cirrhosis were randomized to aldafermin 0.3 mg (n = 7), 1 mg (n = 42), 3 mg (n = 55), or placebo (n = 56) for 48 weeks. The 0.3 mg group was discontinued to limit exposure to suboptimal doses. The primary end point was a change in Enhanced Liver Fibrosis from baseline to week 48. The analyses were performed in the intention-to-treat population. At week 48, the least-squares mean difference in the change in Enhanced Liver Fibrosis was −0.5 (95% CI, −0.7 to −0.2; p = 0.0003) between the 3 mg group and the placebo group. 15%, 21%, and 23% of patients in the placebo, 1 mg, and 3 mg group, respectively, achieved fibrosis improvement ≥ 1 stage; and 13%, 16%, and 20% achieved fibrosis improvement ≥ 1 stage without NASH worsening. Improvement in alanine aminotransferase, aspartate aminotransferase, neoepitope-specific N-terminal pro-peptide of type III collagen, and liver stiffness favored aldefermin groups over placebo. Diarrhea was the most frequent adverse event, occurring at 26% and 40% in the 1 mg and 3 mg groups, respectively, compared to 18% in the placebo group. Overall, 0%, 2%, and 9% of patients in the placebo, 1 mg, and 3 mg group, respectively, discontinued due to treatment-related adverse events. Conclusions: Aldafermin 3 mg resulted in a significant reduction in Enhanced Liver Fibrosis in patients with compensated NASH cirrhosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/hep.0000000000000607

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 18

  1. Noureddin, 2018, NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances, Am J Gastroenterol, 113, 1649, 10.1038/s41395-018-0088-6 · DOI · Paper page
  2. Estes, 2018, Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030, J Hepatol, 69, 896, 10.1016/j.jhep.2018.05.036 · DOI · Paper page
  3. Huang, 2023, Global epidemiology of cirrhosis - aetiology, trends and predictions, Nat Rev Gastroenterol Hepatol, 20, 388, 10.1038/s41575-023-00759-2 · DOI · Paper page
  4. Garcia-Tsao, 2020, Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension, J Hepatol, 72, 885, 10.1016/j.jhep.2019.12.010 · DOI · Paper page
  5. Abdelmalek, 2023, Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study, Clin Gastroenterol Hepatol, S1542-3565(23)00311-7
  6. Davison, 2020, Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials, J Hepatol, 73, 1322, 10.1016/j.jhep.2020.06.025 · DOI · Paper page
  7. DePaoli, 2019, FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis, Diabetes, 68, 1315, 10.2337/db18-1305 · DOI · Paper page
  8. Smirnova, 2022, Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD, Hepatology, 76, 1811, 10.1002/hep.32568 · DOI
  9. Sanyal, 2021, Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases, JHEP Rep, 3, 100255, 10.1016/j.jhepr.2021.100255 · DOI · Paper page
  10. Harrison, 2018, NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, Lancet, 391, 1174, 10.1016/S0140-6736(18)30474-4 · DOI · Paper page
  11. Harrison, 2022, Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): A randomised, double-blind, placebo-controlled, phase 2b trial, Lancet Gastroenterol Hepatol, 7, 603, 10.1016/S2468-1253(22)00017-6 · DOI · Paper page
  12. Noureddin, 2020, Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum, Gastroenterology, 159, 422, 10.1053/j.gastro.2020.04.039 · DOI
  13. Are, 2021, Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis, Clin Gastroenterol Hepatol, 19, 1292, 10.1016/j.cgh.2020.06.070 · DOI
  14. Trembling, 2020, The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease, BMC Gastroenterol, 20, 104, 10.1186/s12876-020-01251-w · DOI
  15. Nielsen, 2013, The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters, Am J Transl Res, 5, 303
  16. Nielsen, 2023, PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease, JHEP Rep, 5, 100743, 10.1016/j.jhepr.2023.100743 · DOI
  17. Rinella, 2019, Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis, J Hepatol, 70, 735, 10.1016/j.jhep.2018.11.032 · DOI · Paper page
  18. Anania, 2021, Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration, Hepatology, 73, 2023, 10.1002/hep.31687 · DOI · Paper page

Cited by

See all 94

Metadata

Authors
Rinella, M. E., Lieu, H. D., Kowdley, K. V., Goodman, Z. D., Alkhouri, N., Lawitz, E., Ratziu, V., Abdelmalek, M. F., Wong, V. W.-S., Younes, Z. H., Sheikh, A. M., Brannan, D., Freilich, B., Membreno, F., Sinclair, M., Melchor-Khan, L., Sanyal, A. J., Ling, L., & Harrison, S. A.
Venue
Hepatology
Published
2023-09-21
Volume
79
Issue
3
Pages
674-689
ISSN
0270-9139 (ISSN-L)
OpenAlex
W4386910070
Cited by
94
References
13
FWCI
15.72
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. https://app.cochat.ai/papers/10.1097/hep.0000000000000607
The paper
Rinella, M. E., Lieu, H. D., Kowdley, K. V., Goodman, Z. D., Alkhouri, N., Lawitz, E., Ratziu, V., Abdelmalek, M. F., Wong, V. W.-S., Younes, Z. H., Sheikh, A. M., Brannan, D., Freilich, B., Membreno, F., Sinclair, M., Melchor-Khan, L., Sanyal, A. J., Ling, L., & Harrison, S. A. (2024). A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. https://doi.org/10.1097/hep.0000000000000607

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.